X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs VENUS REMEDIES - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES VENUS REMEDIES DIVIS LABORATORIES/
VENUS REMEDIES
 
P/E (TTM) x 31.5 -8.9 - View Chart
P/BV x 5.1 0.1 3,697.0% View Chart
Dividend Yield % 1.0 0.0 -  

Financials

 DIVIS LABORATORIES   VENUS REMEDIES
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-17
VENUS REMEDIES
Mar-17
DIVIS LABORATORIES/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,222143 855.7%   
Low Rs78465 1,206.2%   
Sales per share (Unadj.) Rs153.1324.2 47.2%  
Earnings per share (Unadj.) Rs39.96.4 623.2%  
Cash flow per share (Unadj.) Rs44.640.6 109.9%  
Dividends per share (Unadj.) Rs10.000-  
Dividend yield (eoy) %1.00-  
Book value per share (Unadj.) Rs201.8366.0 55.1%  
Shares outstanding (eoy) m265.4712.34 2,151.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.60.3 2,044.1%   
Avg P/E ratio x25.116.2 154.9%  
P/CF ratio (eoy) x22.52.6 878.4%  
Price / Book Value ratio x5.00.3 1,750.6%  
Dividend payout %25.00-   
Avg Mkt Cap Rs m266,2661,282 20,767.6%   
No. of employees `0009.70.9 1,078.1%   
Total wages/salary Rs m4,687251 1,867.5%   
Avg. sales/employee Rs Th4,175.04,430.1 94.2%   
Avg. wages/employee Rs Th481.5278.0 173.2%   
Avg. net profit/employee Rs Th1,089.387.6 1,243.5%   
INCOME DATA
Net Sales Rs m40,6434,000 1,016.0%  
Other income Rs m74923 3,299.1%   
Total revenues Rs m41,3924,023 1,028.9%   
Gross profit Rs m14,460785 1,842.8%  
Depreciation Rs m1,233422 292.5%   
Interest Rs m23344 6.6%   
Profit before tax Rs m13,95342 33,143.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,349-37 -9,051.9%   
Profit after tax Rs m10,60479 13,406.1%  
Gross profit margin %35.619.6 181.4%  
Effective tax rate %24.0-87.9 -27.3%   
Net profit margin %26.12.0 1,319.5%  
BALANCE SHEET DATA
Current assets Rs m40,1052,606 1,538.8%   
Current liabilities Rs m6,5951,980 333.0%   
Net working cap to sales %82.515.6 527.0%  
Current ratio x6.11.3 462.1%  
Inventory Days Days119128 92.4%  
Debtors Days Days8143 187.0%  
Net fixed assets Rs m19,9955,353 373.5%   
Share capital Rs m531123 430.2%   
"Free" reserves Rs m53,0434,393 1,207.6%   
Net worth Rs m53,5744,516 1,186.3%   
Long term debt Rs m01,618 0.0%   
Total assets Rs m61,5858,291 742.8%  
Interest coverage x618.41.1 55,092.4%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.70.5 136.8%   
Return on assets %17.35.1 338.4%  
Return on equity %19.81.8 1,130.1%  
Return on capital %26.16.3 414.8%  
Exports to sales %00-   
Imports to sales %25.218.4 137.1%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m10,259736 1,393.4%   
Fx inflow Rs m35,3840-   
Fx outflow Rs m10,399736 1,412.3%   
Net fx Rs m24,985-736 -3,393.3%   
CASH FLOW
From Operations Rs m11,493997 1,152.5%  
From Investments Rs m-11,372-461 2,465.1%  
From Financial Activity Rs m-93-571 16.3%  
Net Cashflow Rs m28-35 -80.9%  

Share Holding

Indian Promoters % 52.0 32.9 158.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 0.2 6,555.6%  
FIIs % 19.0 0.6 3,275.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 66.4 25.9%  
Shareholders   31,796 20,121 158.0%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   ABBOTT INDIA  NATCO PHARMA  BIOCON LTD  PFIZER  ALKEM LABORATORIES  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 219 Points Lower; Energy and Auto Stocks Witness Selling(Closing)

After witnessing volatile trades during the day, Indian share markets ended their session on a negative note. Losses were largely seen in the oil & gas sector, auto sector.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2%

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY18); Net Profit Up 0.9%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, DIVIS LABORATORIES has posted a net profit of Rs 3 bn (up 0.9% YoY). Sales on the other hand came in at Rs 11 bn (up 2.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jun 25, 2018 03:35 PM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 5-YR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS